Clinical Trial Update: LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial update indicates LSALT peptide is currently recruiting to evaluate prevention or attenuation of acute kidney injury in patients undergoing on-pump…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• LSALT peptide (LSALT peptide)

Snippet

Sponsor: Arch Biopartners Inc. | Conditions: Acute Kidney Injury, Cardiac Surgery | Phase 2 | Status: RECRUITING